US 12,460,190 B2
CRISPR DNA targeting enzymes and systems
David A. Scott, Cambridge, MA (US); David R. Cheng, Boston, MA (US); Winston X. Yan, Boston, MA (US); and Tia M. Ditommaso, Waltham, MA (US)
Assigned to Arbor Biotechnologies, Inc., Cambridge, MA (US)
Appl. No. 17/641,523
Filed by ARBOR BIOTECHNOLOGIES, INC., Cambridge, MA (US)
PCT Filed Sep. 9, 2020, PCT No. PCT/US2020/049923
§ 371(c)(1), (2) Date Mar. 9, 2022,
PCT Pub. No. WO2021/050534, PCT Pub. Date Mar. 18, 2021.
Claims priority of provisional application 62/897,859, filed on Sep. 9, 2019.
Prior Publication US 2022/0282308 A1, Sep. 8, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/22 (2006.01); C12N 1/20 (2006.01); C12N 5/071 (2010.01); C12N 15/11 (2006.01); C12N 15/70 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01); C12Q 1/6823 (2018.01)
CPC C12N 9/22 (2013.01) [C12N 1/20 (2013.01); C12N 5/0687 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/70 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); C12Q 1/6823 (2013.01); C12N 2310/20 (2017.05); C12N 2800/10 (2013.01); C12N 2800/80 (2013.01)] 25 Claims
 
1. An engineered, non-naturally occurring Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) system comprising:
(a) an RNA guide or a nucleic acid encoding the RNA guide, wherein the RNA guide comprises a direct repeat sequence and a spacer sequence capable of hybridizing to a target nucleic acid in a eukaryotic cell; and
(b) a CRISPR-Cas effector protein or a nucleic acid encoding the CRISPR-Cas effector protein, wherein the CRISPR-Cas effector protein comprises an amino acid sequence with at least 95% identity to SEQ ID NO: 10,
wherein the CRISPR-Cas effector protein binds to the RNA guide, and wherein the spacer sequence binds to a target nucleic acid.